Clinical trial NCT06815965: A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Official title: An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Dementia With Lewy Bodies (DLB)
Keywords: Dementia
France
neflamapimod
Lead sponsor: EIP Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: CervoMed, Inc
First posted: 2025-02-10
Enrollment: 20
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Open-label
Primary purpose: OTHER

Brief summary: The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.


Eligibility criteria: Inclusion Criteria:

1. Men and women aged ≥55 years.
2. Subject is willing and able to provide written informed consent.
3. Probable DLB by consensus criteria (McKeith et al, 2017; McKeith et al, 2020).
4. MoCA score ≥18 during Screening.
5. If the patient is currently receiving cholinesterase inhibitor and/or memantine therapy, the patient must have received such therapy for greater than 3 months and on a stable dose for at least 6 weeks at the time of enrollment. Except for reducing the dose for tolerability reasons, the dose of cholinesterase inhibitor may not be modified during the study. If the patient is not currently receiving such therapy, but received such therapy previously, that therapy must have been discontinued at least 3 months prior to enrollment.
6. Normal or corrected eyesight and auditory abilities, sufficient to perform all aspects of the cognitive and functional assessments.
7. No history of learning difficulties that may interfere with their ability to complete the cognitive tests.
8. Received vaccination for SARS-CoV-19 unless medical contraindications prevent being vaccinated or has a history of natural infection.
9. Must have reliable informant or caregiver.

Exclusion Criteria:

1. Diagnosis of any other ongoing central nervous system (CNS) condition other than DLB, including, but not limited to, post-stroke dementia, vascular dementia, Alzheimer's disease (AD), Frontotemporal dementia (FTD), or Parkinson's disease (PD).
2. Ongoing major and active psychiatric disorder and/or other concurrent medical condition that, in the opinion of the Investigator, might compromise safety and/or compliance with study requirements.
3. Suicidality, defined as active suicidal thoughts within 6 months before Screening or at Baseline, defined as answering yes to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS), or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide.
4. Diagnosis of alcohol or drug abuse within the previous 2 years.
5. Poorly controlled clinically significant medical illness, such as hypertension (blood pressure \>180 mmHg systolic or 100 mmHg diastolic); myocardial infarction within 6 months; uncompensated congestive heart failure or other significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would interfere with assessment of drug safety.
6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2 × the upper limit of normal (ULN), total bilirubin \>1.5 × ULN, and/or International Normalized Ratio (INR) \>1.5. If patient is taking blood thinners (e.g., warfarin), and has no known liver issues, INR \>3.
7. Positive screen for human immunodeficiency virus, hepatitis B surface antigen (HbsAg), antibody (anti-HbS), hepatitis C virus (HCV) antibody or evidence of latent or active tuberculosis, active opportunistic or life-threatening infections.
8. Participated in a study of an investigational drug less than 6 weeks or 5 half-lives of an investigational drug, whichever is longer, before enrollment in this study.
9. Receipt of a live vaccine, with the exception of influenza, within 4 weeks before starting study drug treatment.
10. History of previous neurosurgery to the brain within the past five years.
11. If male with female partner(s) of child-bearing potential, unwilling or unable to adhere to contraception requirements specified in the protocol.
12. If female who has not has not reached menopause \>1 year previously or has not had a hysterectomy or bilateral oophorectomy/salpingo-oophorectomy, has a positive pregnancy test result during Screening and/or is unwilling or unable to adhere to the contraception requirements specified in the protocol.
13. If female, currently pregnant or breastfeeding.

Primary outcomes:
measure: Evaluate the safety and tolerability 80 mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
timeFrame: From enrollment until the end of treatment at 24 weeks
measure: Evaluate the safety and tolerability of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
timeFrame: From enrollment until the end of treatment at 24 weeks
measure: Evaluate the maximum plasma concentration (Cmax) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
timeFrame: From enrollment until the end of treatment at 24 weeks
measure: Evaluate the trough plasma concentration (Ctrough) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
timeFrame: From enrollment until the end of treatment at 24 weeks
Secondary outcomes:
measure: Change in ADNI-EF composite score from baseline to 24 weeks
timeFrame: From enrollment until the end of treatment at 24 weeks
measure: Change in CDR-SB score from baseline to 24 weeks
timeFrame: From enrollment until the end of treatment at 24 weeks
measure: Change in TUG test results from baseline to 24 weeks
timeFrame: From enrollment until the end of treatment at 24 weeks
Other outcomes:
measure: Change in MBI-C score from baseline to 24 weeks
timeFrame: From enrollment until the end of treatment at 24 weeks
measure: Changes in DCFS from baseline to 24 weeks
timeFrame: From enrollment until the end of treatment at 24 weeks
measure: Changes hallucinations (PDAP questionnaire) from baseline to 24 weeks
timeFrame: From enrollment until the end of treatment at 24 weeks
measure: Changes in NBM volume from baseline to 16 weeks
timeFrame: From enrollment until 16 weeks
Locations:
city: Strasbourg
country: France
facility: Strasbourg University Hospital (Les Hopitaux Universitaires de Strasbourg)
Study officials:
References: